Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome

Author(s):  Riepl Mike

Issue:  Nov/Dec 2018 - Volume 22, Number 6
View All Articles in Issue

Page(s):  456-465

Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 1
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 2
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 3
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 4
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 5
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 6
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 7
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 8
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 9
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome Page 10

Download in electronic PDF format for $75

Abstract:  Homeostasis of the human vaginal microbiome, which consists of the bacteriome (colonizing bacteria) and the mycobiome (resident fungi), is essential to the health of the female reproductive system. Dysbiosis of either microbial community can be caused by a variety of factors ranging from behavioral issues (personal-hygiene practices, the choice of contraceptives, smoking, etc.) to biological variables (the host-microbiome composition, menstruation, the robustness of the host’s immune response). Clinicians often consult compounding pharmacistsbabout the formulation and use of customized preparations to treat vaginal diseases and re-establish a healthful vaginal microenvironment when commercially manufactured products have failed or are unavailable. In this article, the function of the human vaginal bacteriome and mycobiome are examined, a common microorganism identified in each of those microenvironments is discussed, factors that cause dysbiosis are reviewed, and the role of biofilm in the vaginal microbiota is explored. A question typical of those asked by prescribers committed to improving women’s health and decreasing the incidence of recurring bacterial vaginosis or fungal infections is answered. Formulations for compounds that help ensure or reestablish the homeostasis of the human vaginal bacteriome and mycobiome are also provided.

Related Keywords: Mike Riepl, RPh, colonizing bacteria, mycobiome, resident fungi, female reproductive system, dysbiosis, vagina, vaginal microenvironment, vaginal microbiota, vaginal bacteriome, Lactobacillus species, Candida species, candidiasis, C albicans, vaginal mucobiome, biofilms, fungi, fungus, vaginal suppository, lactobacilli, vaginal health, menopause, boric acid vaginal suppositories, estriol vaginal cream, formulations, Lactobacillus acidophilus, women, bacterial vaginosis, fungus infection, fungal infection

Related Categories: FORMULATIONS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, INFECTIOUS DISEASE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome
Riepl Mike
Nov/Dec 2018
Pg. 456-465

Gentian Violet Vaginal Suppositories
Allen Loyd V Jr
Nov/Dec 2009
Pg. 556

Case Report of a Human Papillomavirus Infection Treated with Green Tea Extract and Curcumin Vaginal Compounded Medications
Agbi Kelechi E
, Hover Sara, Carvalho Maria
May/Jun 2018
Pg. 196-202

Mupirocin 1% (20-mg) Vaginal Suppository
Allen Loyd V Jr
Jul/Aug 2009
Pg. 338

Estradiol 0.1% Vaginal Solution
Allen Loyd V Jr
Sep/Oct 2008
Pg. 450

Nystatin 100,000-units Vaginal Inserts
Allen Loyd V Jr
Jul/Aug 2016
Pg. 322

Estradiol 0.1% Vaginal Solution
Allen Loyd V Jr
Jan/Feb 2024
Pg. 58

Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy
Laque Larissa C
, Raposo Nádia RB, Fernandes Brandão Marcos Antônio, de Oliveira Ferreira Anderson, Polonini Hudson C
Jan/Feb 2019
Pg. 77-81

Clindamycin 100-mg Vaginal Suppositories
Allen Loyd V Jr
Jul/Aug 2009
Pg. 334

Clotrimazole 500-mg Vaginal Suppositories
Allen Loyd V Jr
Nov/Dec 2003
Pg. 469

Physical and Chemical Stability of Estriol 0.025% to 1% Vaginal Creams (VersaBase)
Ip Kendice
, Shan Ashley, Yan Wei, Banov Daniel
Nov/Dec 2018
Pg. 504-511

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Vulvovaginal Symptoms in a Postmenopausal Woman: A Case Study
Lima Ramona
, Gonzalez Mark A, Urwin Craig, Jean Linda, Carvalho Maria, Banov Fabiana
Mar/Apr 2023
Pg. 108-112

Estrogen 0.625-mg/5-g Vaginal Gel
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 185

Sildenafil 1% Vaginal Cream or Gel
Allen Loyd V Jr
Mar/Apr 2005
Pg. 153

Sildenafil Vaginal Suppository
Allen Loyd V Jr
Mar/Apr 2005
Pg. 154

Boric Acid 600-mg Vaginal Suppository
Allen Loyd V Jr
Jan/Feb 2004
Pg. 52

Estriol 2-mg/g with Estradiol 0.5-mg/g Vaginal Cream
Allen Loyd V Jr
Sep/Oct 2001
Pg. 375

Amphotericin B 40-mg Vaginal Suppositories
Allen Loyd V Jr
Nov/Dec 1998
Pg. 436

Estrogen 0.625-mg/5-g Vaginal Gel
Allen Loyd V Jr
Nov/Dec 2000
Pg. 460

Return to Top